We serve Chemical Name:6-methoxypicolinamide CAS:98276-69-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-methoxypicolinamide
CAS.NO:98276-69-8
Synonyms:6-Methoxypicolinamide;6-methoxy-2-pyridinecarboxamide;6-Methoxy-pyridine-2-carboxylic acid amide
Molecular Formula:C7H8N2O2
Molecular Weight:152.15100
HS Code:2933399090
Physical and Chemical Properties:
Melting point:108-109ºC
Boiling point:285ºC at 760mmHg
Density:1.213g/cm3
Index of Refraction:1.55
PSA:65.21000
Exact Mass:152.05900
LogP:0.88940
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 6-Methoxypicolinamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Methoxy-pyridine-2-carboxylic acid amide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-methoxy-2-pyridinecarboxamide Use and application,6-Methoxy-pyridine-2-carboxylic acid amide technical grade,usp/ep/jp grade.
Related News: Inceptua has global operations with local offices across Europe, USA, and Asia 6-methoxypicolinamide manufacturer Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 6-methoxypicolinamide supplier Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 6-methoxypicolinamide vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 6-methoxypicolinamide factory If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said.
